AXSM Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
218.4M
+14.2%
191.2M
-2.4%
196.0M
+14.6%
171.0M
+14.0%
150.0M
Cost of Revenue
13.6M
-7.9%
14.7M
+19.4%
12.3M
+3.5%
11.9M
-11.4%
13.4M
Gross Profit
204.8M
+16.1%
176.5M
-3.9%
183.7M
+15.5%
159.1M
+16.5%
136.6M
Operating Expenses
254.5M
+6.1%
239.8M
+13.9%
210.6M
+2.7%
205.2M
+18.4%
173.3M
R&D
46.2M
-12.2%
52.7M
+8.0%
48.8M
+21.5%
40.2M
-18.9%
49.5M
SG&A
208.1M
+12.5%
185.0M
+9.3%
169.3M
+12.7%
150.2M
+15.3%
130.3M
Operating Income
-49646000
+21.6%
-63357000
-135.0%
-26957000
+41.5%
-46109000
-25.6%
-36714000
EBITDA
-47914000
+22.3%
-61669000
-144.4%
-25236000
+43.1%
-44382000
-26.8%
-35005000
Net Income
-51314000
+20.5%
-64542000
-126.0%
-28559000
+39.5%
-47229000
+1.6%
-47973000
EPS (Basic)
$-0.99
+21.4%
$-1.26
-125.0%
$-0.56
+40.4%
$-0.94
+3.1%
$-0.97
EPS (Diluted)
$-0.99
+21.4%
$-1.26
-125.0%
$-0.56
+40.4%
$-0.94
+3.1%
$-0.97
Shares (Diluted)
51.8M
+1.2%
51.2M
+1.1%
50.7M
+1.3%
50.0M
+1.2%
49.4M
Axsome Therapeutics (AXSM) โ€” Financials